Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA1H | O95180 | 2/20 | 0.46 |
| ▸ | CACNA1F | O60840 | 7/20 | 0.45 |
| ▸ | CACNA1D | Q01668 | 7/20 | 0.45 |
| ▸ | CACNA1S | Q13698 | 7/20 | 0.45 |
| ▸ | CACNA1C | Q13936 | 7/20 | 0.45 |
| ▸ | MEN1 | O00255 | 3/20 | 0.41 |
| ▸ | MAPT | P10636 | 3/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | ADRA1D | P25100 | 2/20 | 0.40 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.40 |
| ▸ | ADRA1B | P35368 | 2/20 | 0.40 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.40 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.40 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.40 |
| ▸ | HIF1A | Q16665 | 3/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5569439 | 0.93 | CACNA1H (0.46) | CACNA1HCACNA1FCACNA1DCACNA1SCACNA1C | |
| SCHEMBL5567747 | 0.91 | CACNA1H (0.46) | CACNA1HCACNA1FCACNA1DCACNA1SCACNA1C | |
| SCHEMBL5563148 | 0.91 | CACNA1H (0.46) | CACNA1HCACNA1FCACNA1DCACNA1SCACNA1C | |
| SCHEMBL5567117 | 0.86 | CACNA1H (0.47) | CACNA1HCACNA1FCACNA1DCACNA1SCACNA1C | |
| SCHEMBL5568239 | 0.86 | CACNA1H (0.47) | CACNA1HCACNA1FCACNA1DCACNA1SCACNA1C | |
| SCHEMBL5562863 | 0.86 | CACNA1H (0.47) | CACNA1HCACNA1FCACNA1DCACNA1SCACNA1C | |
| SCHEMBL5568435 | 0.84 | CACNA1H (0.46) | CACNA1HCACNA1FCACNA1DCACNA1SCACNA1C | |
| SCHEMBL5563125 | 0.84 | CACNA1C (0.47) | CACNA1HCACNA1FCACNA1DCACNA1SCACNA1C | |
| SCHEMBL5563911 | 0.83 | CACNA1H (0.47) | CACNA1HCACNA1FCACNA1DCACNA1SCACNA1C | |
| SCHEMBL5568636 | 0.83 | CACNA1H (0.48) | CACNA1HCACNA1FCACNA1DCACNA1SCACNA1C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7166603-B2 | Dihydropyrimidone inhibitors of calcium channel function | BRISTOL-MYERS SQUIBB CO. (US) | 2007-01-23 | — | — | US | claimed |
| US-20050043339-A1 | Dihydropyrimidone inhibitors of calcium channel function | BRISTOL-MYERS SQUIBB COMPANY | 2005-02-24 | — | — | US | claimed |
| US-7166603-B2 | Dihydropyrimidone inhibitors of calcium channel function | BRISTOL-MYERS SQUIBB CO. (US) | 2007-01-23 | — | — | US | disclosed |
| US-20050043339-A1 | Dihydropyrimidone inhibitors of calcium channel function | BRISTOL-MYERS SQUIBB COMPANY | 2005-02-24 | — | — | US | disclosed |
| WO-2005009392-A2 | DIHYDROPYRIMIDONE INHIBITORS OF CALCIUM CHANNEL FUNCTION | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-02-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050043339-A1 | Dihydropyrimidone inhibitors of calcium channel function | CACNA1E, CACNA1C, CACNA1S | CACNA1H 10/4885CACNA1F 6/4885CACNA1D 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.